Europe's decades-long decline in pharmaceutical R&D and delay in patient access to medicines are the direct result of government policies designed to lower spending on innovative medicines, including direct drug price controls, antiquated comparators for health technology assessment (HTA), international reference pricing, revenue claw backs, and parallel trade. Even countries such as Denmark, with a budget surplus and GDP like the US, continues to institute policies that burden patients with delayed access to innovation. Under the Trump Administration, the US has said that it expects wealthy countries to shoulder their “fair share” of R&D investments and pay drug prices relative to US GDP. Our panel will argue that this is an opportunity for the EU to reorient its economy around biotech investment and economic growth. Furthermore, speakers will discuss global drug pricing and investment trends in the US, Europe, and China, and explore how companies and policymakers can work together to design innovative pricing and access strategies that support biotech innovation at prices that are sustainable for innovators and payers alike.